{"eventGroups":[{"description":"Gefitinib 250 mg daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.","id":"EG000","otherNumAffected":37,"otherNumAtRisk":37,"seriousNumAffected":0,"seriousNumAtRisk":37,"title":"Gefitinib"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":37,"numEvents":11}],"term":"Anorexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":37,"numEvents":30}],"term":"Diarrhea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":37,"numEvents":8}],"term":"Dry skin"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":37,"numEvents":16}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":37,"numEvents":8}],"term":"Rash/desquamation"}],"timeFrame":"Adverse events collected every four weeks during treatment at regular assessment, participation expected up to 12 months."}